中国药理学通报2016，Vol.32Issue(8)：1049-1052,4.DOI:10.3969/j.issn.1001-1978.2016.08.004
靶向 CD123嵌合抗原受体T 细胞治疗急性髓系白血病最新进展
Research progress of T cells expressing CD123 chimeric antigen receptor for treatment of AML
摘要
Abstract
Acute myeloid leukemia ( AML) is the most common acute leukemia in adults and has the highest death rate of all leukemias. Compared with other hematologic malignancies , there was only a small increment in the 5-year relative overall survival for patients with AML in the last 40 years, despite the advancement in our understanding of AML .CD123 is an AML-associated antigen that expresses at a high level in leukemic stem cells and leukemic blasts and a low level in normal hematopoiet-ic stem cells.As an attractive surface target for AML therapies , immune-based therapies targeting CD 123 are being developed re-cently, especially chimeric antigen receptor ( CAR) T-cell-based immunotherapy .Preclinical data have demonstrated that CD 123 CAR-T cells exhibit potent antileukemic activity and various im-pacts on normal hematopoiesis .This will probably be a promis-ing treatment for patients with relapsed/refractory AML.关键词
急性髓系白血病/CD123/干细胞/免疫治疗/嵌合抗原受体/T细胞Key words
AML/CD123/stem cells/immune-based therapies/CAR/T cells分类
医药卫生引用本文复制引用
张家奎,阮燕洁,王会平,翟志敏..靶向 CD123嵌合抗原受体T 细胞治疗急性髓系白血病最新进展[J].中国药理学通报,2016,32(8):1049-1052,4.基金项目
国家自然科学基金资助项目（ No 81401293）；安徽高校省级自然科学研究重大项目 （）
